Nutriband Inc. (NASDAQ: NTRB) 2024 Milestones and 2025 Commercialization Goals FAQ
Summary
What is Nutriband Inc.’s main focus in 2024 and 2025?
Nutriband Inc. is focusing on advancing its AVERSA abuse-deterrent transdermal technology, transitioning from feasibility to commercial development of AVERSA Fentanyl in partnership with Kindeva Drug Delivery, and targeting a pivotal Human Abuse Liability clinical trial and NDA filing.
What are the expected peak annual sales for AVERSA Fentanyl and AVERSA Buprenorphine?
AVERSA Fentanyl and AVERSA Buprenorphine could reach peak annual sales of up to $200 million and $130 million respectively.
How has Nutriband expanded its global patent portfolio?
Nutriband has expanded its global patent portfolio to 46 countries.
How much did Nutriband raise in its non-brokered placement?
Nutriband raised $8.4 million in a non-brokered placement.
What drives Nutriband’s expected revenue growth in 2025?
Nutriband expects continued revenue growth in 2025 from its Pocono Pharma subsidiary, driven by its partnership with KT Tape.
What is AVERSA technology?
AVERSA technology is an abuse-deterrent technology that can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Where can I find more information about Nutriband Inc.?
For more information about Nutriband Inc., visit www.Nutriband.com.
Where can I view the full article about Nutriband Inc.’s shareholder letter?
To view the full article, visit https://ibn.fm/NGtih.
What is BioMedWire?
BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, part of the Dynamic Brand Portfolio @ IBN.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 118496